ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 176

SEC16A and Antigen Presentation Abnormalities in the Pathogenesis of Axial Spondyloarthritis

Fanxing Zeng1, Vidya Ranganathan2, Proton Rahman3, Darren O’Rielly4 and Nigil Haroon5, 1University Health Network, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 4Memorial University, St John's, NF, Canada, 5Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: antigen-presenting cells and axial spondyloarthritis, ER Stress, Immune Dysregulation, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Axial Spondyloarthritis (AxSpA) is a chronic inflammatory rheumatic disease of axial skeleton. Our group recently identified a novel rare mutation of the SEC16A gene that strongly tracked with AxSpA in a multiplex family. Remarkably, all individuals with HLA-B27 and the SEC16A mutation had or went on to develop AxSpA. Sec16a is an important player in the ER-Golgi transport pathway with potential effects on antigen presentation and the pathogenesis of AxSpA. We have previously shown that the SEC16A mutation hinders the assembly of COPII vesicles budding from the ER that leads to abnormal MHC I trafficking and ER stress. In this study we explore the functional impact of Sec16A abnormalities on CD8+ T cell immune response. In addition, protein-protein interaction assays followed by pathway analysis help us understand the impact of SEC16A mutation on different cellular processes.

Methods:

AxSpA patients from the multiplex family (N=9) had both SEC16A mutation and HLA-B27. Controls (N=5) were family members with no disease and had HLA-B27 and wild-type (WT) SEC16A. B cell lines were generated from patients and controls by EBV transformation. For validation, SEC16A was silenced in B-lymphoblastoid cells with stable HLA-B27 expression (C1R-B27) and assays repeated. Total protein was extracted from B cells and the formation of HLA free heavy chain homodimer (FHC) was studied using HC-10 western blot under non-reducing and reducing conditions. HLA-B27 mediated immune response was assessed by cytotoxic T-lymphocyte assay. NP383-391 specific CTL clones were generated from HLA-B27 positive donor. The GFP-ubiquitin-NP383-391 construct was introduced by DNA transfection in B cells. Two days after transfection, B cells were incubated with NP383-391 specific CTL at a ratio of 1:10 for 4 hours. CTL activity was evaluated using caspase 3 cleavage in target cells. Pathway analysis assessed by protein-protein interaction was carried out to investigate the interactome of SEC16A variants.

Results:

Both SEC16A mutation in patients’ B cells and Sec16a deficiency (90% suppression) in C1R-B27 significantly (P<0.01 and P<0.001 respectively) increased the level of HLA-B27 FHC homodimers. This is likely due to a general disruption of MHC I trafficking by Sec16A abnormalities as we previously reported. GFP-ubiquitin-NP383-391 constructs were stably expressed in EBV-B cells at a similar level without having an effect on HLA-B27 surface expression. However, the cytotoxicity of NP 383-391 specific T cells were significantly lower against EBV-B cells with mutant SEC16A compared to EBV-B cells with WT SEC16A (p<0.01). T cell cytotoxicity was almost completely abolished in SEC16A-suppressed C1R-B27 cells. Using protein-protein interaction and pathway analysis, we found that mutant Sec16a had lower affinity to interactors involved in ER-to-Golgi vesicle mediated transport, membrane budding, vesicle organization, and antigen processing/presentation.

Conclusion:

Sec16a abnormalities can affect HLA-B27 intracellular transport, dimerization, antigen presentation and cytotoxic T cell responses. These changes can potentially play a role in AS pathogenesis.


Disclosure: F. Zeng, None; V. Ranganathan, None; P. Rahman, Janssen Pharmaceutica Product, L.P., 8,Amgen, AbbVie, BMS, Celgene, Pfizer, Janssen, Wyeth, EliLiiy, Novartis, 8,Amgen, AbbVie, BMS, Celgene, Pfizer, Janssen, Wyeth, EliLiiy, Novartis, 5; D. O’Rielly, None; N. Haroon, None.

To cite this abstract in AMA style:

Zeng F, Ranganathan V, Rahman P, O’Rielly D, Haroon N. SEC16A and Antigen Presentation Abnormalities in the Pathogenesis of Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/sec16a-and-antigen-presentation-abnormalities-in-the-pathogenesis-of-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sec16a-and-antigen-presentation-abnormalities-in-the-pathogenesis-of-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology